STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating. Now, though, that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this…
ImpactNotable 33/100
Why it mattersRule-based estimate: no strong signals; trust 8/10.
Regions🌐 Global
Published17 h ago (Mon, 14 Sep 2026 13:07:51 GMT)
RetrievedMon, 14 Sep 2026 17:39:54 GMT via rss
ClassifiedMon, 14 Sep 2026 17:40:00 GMT by heuristic
AuthorEd Silverman